Grundner-Culemann E, Bokemeyer C, Neubauer V, Shalitin C, Schmoll H J, Poliwoda H, Benter T
Department of Hematology and Oncology, Hannover University Medical School, Germany.
J Cancer Res Clin Oncol. 1993;119(11):685-8. doi: 10.1007/BF01215988.
A novel protein of 21 kDa (p21) has been detected in the sera of patients with different solid tumors. The serum levels of this p21 protein were measured in seven patients with metastatic testicular germ-cell tumors before and after chemotherapy using an enzyme-linked immunosorbent assay. In five out of six patients who responded to chemotherapy a concomitant decrease of p21 serum levels was found. The decrease of p21 was in accordance with the decline of the established tumor markers alpha-fetoprotein, human chorionic gonadotropin beta-subunit and lactate dehydrogenase in three patients with non-seminomatous tumors and with the decline of lactate dehydrogenase and the clinical response in two patients with seminoma. In one patient the predicted decline of p21 did not occur despite the patient's clinical response to chemotherapy. In the seventh patient, who relapsed directly after chemotherapy, no decline of either p21 levels or tumor markers was observed. The absolute amount of the p21 protein prior to chemotherapy did not correlate with the patients' tumor burden. Elevated levels of p21 were found in patients with seminomatous and non-seminomatous germ-cell tumors. Since seminoma patients do not secrete tumor markers like alpha-fetoprotein or human chorionic gonadotropin beta, the determination of p21 levels may help to evaluate the efficacy of chemotherapy in patients with seminomatous as well as in patients with marker-negative non-seminomatous germ-cell tumors. The biological role of p21 and its clinical significance will be further investigated.
在患有不同实体瘤的患者血清中检测到一种新型的21 kDa蛋白（p21）。使用酶联免疫吸附测定法，对7例转移性睾丸生殖细胞肿瘤患者化疗前后的血清p21蛋白水平进行了测量。在6例对化疗有反应的患者中，有5例患者的血清p21水平同时下降。p21的下降与3例非精原细胞瘤患者中已确定的肿瘤标志物甲胎蛋白、人绒毛膜促性腺激素β亚基和乳酸脱氢酶的下降相一致，也与2例精原细胞瘤患者中乳酸脱氢酶的下降及临床反应相一致。在1例患者中，尽管对化疗有临床反应，但p21并未出现预期的下降。在第7例患者中，化疗后直接复发，未观察到p21水平或肿瘤标志物下降。化疗前p21蛋白的绝对量与患者的肿瘤负荷无关。在精原细胞瘤和非精原细胞瘤生殖细胞肿瘤患者中均发现p21水平升高。由于精原细胞瘤患者不分泌甲胎蛋白或人绒毛膜促性腺激素β等肿瘤标志物，因此测定p21水平可能有助于评估精原细胞瘤患者以及标志物阴性的非精原细胞瘤生殖细胞肿瘤患者的化疗疗效。p21的生物学作用及其临床意义将进一步研究。
